These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 1553575)
1. Principles of combining biomodulators with cytotoxic agents in vivo. Mitchell MS Semin Oncol; 1992 Apr; 19(2 Suppl 4):51-6. PubMed ID: 1553575 [TBL] [Abstract][Full Text] [Related]
2. Combining chemotherapy with biological response modifiers in treatment of cancer. Mitchell MS J Natl Cancer Inst; 1988 Nov; 80(18):1445-50. PubMed ID: 3054127 [TBL] [Abstract][Full Text] [Related]
3. [Immunomodulation in cancer. What do we do and where do we go?]. Rodríguez Orozco AR; Serriteño NM Rev Alerg Mex; 2005; 52(2):96-101. PubMed ID: 16158783 [TBL] [Abstract][Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428 [TBL] [Abstract][Full Text] [Related]
6. [Augmentation of antitumor immunity in cancer chemotherapy]. Hosokawa M; Kobayashi H Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1402-6. PubMed ID: 1697151 [TBL] [Abstract][Full Text] [Related]
7. The use of biomodulators to potentiate chemotherapy in the treatment of cancer. Mitchell MS Cancer Invest; 1990; 8(2):279-80. PubMed ID: 2400947 [No Abstract] [Full Text] [Related]
8. Need for immunologic stimulators during immunosuppression produced by major cancer surgery. Cole WH; Humphrey L Ann Surg; 1985 Jul; 202(1):9-20. PubMed ID: 3893336 [TBL] [Abstract][Full Text] [Related]
9. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies. Stevenson HC; Klein HG Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018 [No Abstract] [Full Text] [Related]
11. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Terranova-Barberio M; Thomas S; Munster PN Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539 [TBL] [Abstract][Full Text] [Related]
12. The immunoaugmenting effects of cancer chemotherapeutic agents. Mastrangelo MJ; Berd D; Maguire H Semin Oncol; 1986 Jun; 13(2):186-94. PubMed ID: 2940686 [TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive therapy using cytostatics]. Schumacher K; Ricken D Internist (Berl); 1971; 12():Suppl 1:142-8. PubMed ID: 4944100 [No Abstract] [Full Text] [Related]
14. Immunomodulation by cancer chemotherapeutic agents. Periti P; Mini E Chemioterapia; 1987 Dec; 6(6):399-402. PubMed ID: 3325174 [TBL] [Abstract][Full Text] [Related]
15. [Antitumor immunoadjuvant activity and the immunoregulatory mechanisms of yeasts and their components]. Marconi P; Bistoni F Ann Ist Super Sanita; 1982; 18(3):501-8. PubMed ID: 6765083 [No Abstract] [Full Text] [Related]
16. Effects of anticancer drugs on the immune system in humans. Ehrke MJ; Mihich E; Berd D; Mastrangelo MJ Semin Oncol; 1989 Jun; 16(3):230-53. PubMed ID: 2658084 [No Abstract] [Full Text] [Related]
17. Immunomodulation in cancer therapeutics. Ehrke MJ Int Immunopharmacol; 2003 Aug; 3(8):1105-19. PubMed ID: 12860167 [TBL] [Abstract][Full Text] [Related]
18. Biologic agents as modifiers of chemotherapeutic effects. Parmiani G; Rivoltini L Curr Opin Oncol; 1991 Dec; 3(6):1078-86. PubMed ID: 1843110 [TBL] [Abstract][Full Text] [Related]
19. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Emens LA; Jaffee EM Cancer Res; 2005 Sep; 65(18):8059-64. PubMed ID: 16166275 [TBL] [Abstract][Full Text] [Related]